Recombinant anticoccidial vaccines - a cup half full?

Area of Science:

• Veterinary Parasitology
• Vaccine Development
• Poultry Health

Background:

• Coccidiosis, caused by Eimeria species, significantly impacts chicken production.
• Current control relies on husbandry, chemoprophylaxis, and live vaccines, but scalable subunit/recombinant vaccines are needed.
• Numerous candidate antigens show promise in experimental models but haven't reached commercialization.

Purpose of the Study:

• To evaluate the potential of combining existing Eimeria antigens for novel multi-valent anticoccidial vaccines.
• To explore how antigenic diversity and parasite evolution inform vaccine antigen selection.
• To identify optimal delivery systems for future vaccine development.

Main Methods:

• Review of experimental data on candidate anticoccidial vaccine antigens.
• Analysis of Eimeria antigenic diversity and genomic evolution.
• Consideration of vaccine breakthrough risks and efficacy thresholds.

Main Results:

• Some Eimeria antigens demonstrate protective efficacy, though often at the lower end compared to existing controls.
• Antigenic diversity and parasite evolution rates are critical factors for vaccine longevity.
• Apical membrane antigen 1 (AMA1) and immune mapped protein 1 (IMP1) are examples of antigens with available diversity data.

Conclusions:

• Combinations of previously identified antigens may form the basis of effective multi-valent anticoccidial vaccines.
• Understanding parasite evolution and antigenic diversity is key to selecting optimal vaccine components.
• Further research into delivery systems is necessary for successful vaccine implementation.